UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/566,132	07/07/2006	Antoni Torrens Jover	283498US0PCT	1949
22850 7590 10/12/2007 OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, P.C. 1940 DUKE STREET			EXAMINER	
			THOMAS, TIMOTHY P	
ALEXANDRIA	ALEXANDRIA, VA 22314		ART UNIT	PAPER NUMBER
			1614	
			NOTIFICATION DATE	DELIVERY MODE
			10/12/2007	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication...

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com oblonpat@oblon.com jgardner@oblon.com

	Application No.	Applicant(s)				
	10/566,132	TORRENS JOVER ET AL.				
Office Action Summary	Examiner	Art Unit				
	Timothy P. Thomas	1614				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
Responsive to communication(s) filed on <u>27 Ja</u> This action is FINAL . 2b)⊠ This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro					
Disposition of Claims						
4) ⊠ Claim(s) 1-45 is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 1-45 are subject to restriction and/or expressions.	wn from consideration.					
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicated any not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	epted or b) objected to by the l drawing(s) be held in abeyance. Sec tion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119		·				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate				

Art Unit: 1614

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-11, 32-45 drawn to an active substance combination comprising at least one 2,5-dihydroxybenzenesulfonic compound and at least one potassium ion channel modulator.

Group II, claim(s) 12-31, drawn to a method for the manufacture of a medicament.

Group III, claim(s) 12-31, drawn to a method for the prophylaxis and/or treatment of various diseases.

Note: Claims 12-31, drafted as "use" claims, may be interpreted in either of two ways, as indicated for Groups II and III. If an election is made of Group II or III applicant should amend these claims to clearly reflect applicant's intent.

2. The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature linking groups I-III is a combination of a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator. Esteve-Soler, et al. (US 2004/0143010 A1; priority date 2001) teaches a combination of a 2,5-dihidroxybenzenosulphonic acid, including calcium dobesilate, ethamsylate, and

Art Unit: 1614

persilate and nicorandyl (a potassium channel opener) (abstract; examples 1-3). Since the combination has previously been taught in the prior art the technical feature lacks novelty. Therefore, the technical feature linking the inventions of groups I-III does not constitute a special technical feature as defined by PCT Rule 13.2 as it does not define a contribution over the prior art.

Accordingly, Groups I-III are not so linked by the same of a corresponding special technical feature as to form a single inventive concept.

3. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

For any group elected, applicant is required to elect:

- (i) a single disclosed or a disclosed combination of 2,5-dihydroxybenzenesulfonic compound specie(s), including the cation(s) (e.g., from one of claims 3-5 and claim 2);
- (ii) a single disclosed a disclosed combination of potassium ion channel modulator compound specie(s) (e.g., from the compounds recited in claim 7); and
- (iii) a single disclosed disease or condition (e.g., a specie recited in claims 11-31); and

For any group elected, applicant is also required to specify:

Art Unit: 1614

(iv) whether a further active substance specie is present (claims 10, 32); if the election is made that a further specie is present, applicant is also required to elect:

- (iva) a single disclosed further active compound specie

 If Group I is elected, applicant is also required to specify:
- (v) whether the formulation comprises a sustained-release form (claim 36); if the election is made that a sustained-release form is present, applicant is also required to elect:
 - (va) coating or matrix (claim 37); and
 - (vb) a single disclosed or disclosed mixture of sustained release material(s) (e.g., a single type of acrylic resin such as polymethacrylate (claim 39), a cellulose derivative such as ethyl cellulose (claim 40) or a wax such as carnauba wax (claim 41)).

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims

Art Unit: 1614

are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

- 4. The claims are deemed to correspond to the species listed above in the following manner:
- (i) All claims
- (ii) All claims
- (iii) Claims 11-31
- (iv) absent: all claims; present: claims 10-11, 32-45;
- (v) with sustained-release component: claims 36-44; without sustained-release component: claims 1-11, 32-35, 43-45

The following claim(s) are generic: claim 1, and 8-9 (when dependent on claim 1).

5. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

As pointed out above, Esteve-Soler, et al. teaches the combination of a 2,5 dihidroxybenzenosulphonic acid, and a potassium channel opener. Since the technical feature has been disclosed in the prior art the technical feature linking the species lacks novelty and the species do not relate to a single general inventive concept.

6. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Timothy P. Thomas whose telephone number is (571) 272-8994. The examiner can normally be reached on Monday-Thursday 6:30 a.m. - 5:00 p.m..

Application/Control Number: 10/566,132 Page 7

Art Unit: 1614

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on (571) 272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/TPT/ Timothy P. Thomas Patent Examiner ARDIN H. MARSCHEL SUPERVISORY PATENT EXAMINER